Found 72 articles
Two Chemical Series Identified to Facilitate Lead Optimisation Activities.
Each Unit is comprised of one common share (each, a "Common Share") in the capital of the Company and one-half of one whole Common Share purchase warrant (each whole warrant, a "Warrant").
Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments
The flagship London clinic is Awakn's third clinic, adding to the Company's two operating clinics located in Bristol (UK) and Oslo (Norway).
Brings Over 20 Years of Commercial Biotech Experience to Lead Awakn's Therapeutics Commercialization Activities in the U.S.
Awakn Life Sciences is a biotechnology company, researching, developing, and delivering psychedelic therapeutics to treat addiction.
Awakn Life Sciences Drug Discovery Program Files Patent Application for a New Class of Entactogen-Like Molecules
Entactogen NCE Series Enhances the Potential to Treat a Broad Range of Addictions.
Awakn Life Sciences' Professor Celia Morgan Named One of the Most Influential Women in the Psychedelics Industry
Professor Morgan, Awakn's Head of Ketamine-Assisted Therapy for Addiction, Named One Of The 16 Most Influential Women Shaping The Future Of Psychedelics By Insider.
Awakn Life Sciences to Host Fireside Chat with Dr. Ben Sessa, Chief Medical Officer, on March 2nd at 11:00am EST
Dr. Sessa Will Discuss the Promise of Psychedelic Medicine in Treating Addiction.
Awakn Life Sciences Files Patent Application for a New Class of Entactogen-Like Molecules to Treat a Broad Range of Addictions
Novel Entactogen NCE Series Enhances the Potential for Improved Treatment of Addiction.
Agreement to Explore a Partnership for MDMA-Assisted Therapy for Treatment of Alcohol Use Disorder in Europe.
. Upon review, the Company determined that a third party, which was not engaged by the Company or any of its officers, directors, controlling shareholders or any third-party service providers distributed promotional emails.
Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial
Primary and Secondary Endpoints Achieved, Including 86% Abstinence Over 6 Months Post Treatment and No Serious Adverse Events.
Awakn Life Sciences Announces Voluntary Lock-up Agreement Extension with Management, Board of Directors and Key Shareholders
Management, the Board of Directors, and key shareholders represent approximately 11.5 million shares or 46.1% of the issued and outstanding shares.
All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified.
Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, as Independent Member of its Board of Directors
Paul Carter is a seasoned international BioPharma leader with an outstanding and proven track record.
Kate Butler to Be Appointed CFO; Jonathan Held, Current CFO, to Be Appointed Chief Business Officer
Awakn Life Sciences Signs MOU with NHS (Devon Partnership NHS Trust) and University of Exeter with a View of Increasing Access to Psychedelic-Assisted Psychotherapy in the UK
The partnership establishes a framework and strategic relationship to assess NHS organizational readiness for ketamine-assisted psychotherapy.
Mind Cure Health Inc. is pleased to provide an operational progress update on the strategic initiatives of its operating segments
Awakn Life Sciences Announces the Findings from the Phase II A/B Study Are to Be Published in the American Journal of Psychiatry
World's First Controlled Study to Investigate Ketamine-Assisted Psychotherapy.
Prof. Nutt and Dr. Sessa and will present together live on The Future of Addiction Treatments panel on Tuesday, November 9th at 2:00 p.m. ET. Register to attend here.